The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

NCT06605300 | Completed

• 1 other identifier: UESTC-neuSCAN-96
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 2

Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.

Conditions

Healthy

Keywords

oxytocin; vasopressin; delta-beta coupling

Outcome Measures

Primary Outcomes (3)

• Resting-state EEG

  Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index.

  35-50 minutes after treatment administration.

• Behavioral indices in the tasks

  Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious).

  50-90 minutes after treatment administration.

• Task-based EEG

  EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses.

  50-90 minutes after treatment administration.

Secondary Outcomes (1)

• SCR in anxiety induction

  70-90 minutes after treatment administration.

Study Arms (3)

oxytocin

EXPERIMENTAL

A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril.

Drug: Intranasal Oxytocin (IN-OXT)

vasopressin

EXPERIMENTAL

A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril.

Drug: Intranasal Vasopressin (AVP)

placebo

PLACEBO COMPARATOR

A single dose of placebo will be administered with 3 puffs of treatment to each nostril.

Drug: Intranasal Placebo

Interventions

Intranasal Oxytocin (IN-OXT) DRUG

Subject assigned to receive intranasal administration of oxytocin (24 IU).

oxytocin

Intranasal Vasopressin (AVP) DRUG

Subjects assigned to receive intranasal administration of vasopressin (20 IU).

vasopressin

Intranasal Placebo DRUG

Subjects assigned to receive intranasal administration of placebo.

placebo

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects without past or current psychiatric or neurological disorders.

You may not qualify if:

• History of head injury.
• Pregnant,menstruating,taking oral contraceptives.
• Medical or psychiatric illness.

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (2)

University of Electronic Science and Technology of China

Chengdu, Chengdu, 611731, China

Location

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, 611731, China

Location

MeSH Terms

Conditions

Diabetes Insipidus

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Study Officials

• Shuxia Yao, Dr

  University of Electronic Science and Technology of China

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: September 18, 2024
• First Posted: September 20, 2024
• Study Start: October 2, 2024
• Primary Completion: July 28, 2025
• Study Completion: August 12, 2025
• Last Updated: October 3, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)